Infant Bacterial Therapeutics AB(SE:IBT.B)
kr 66.00-7.30 (-9.96%)
SE:IBT.B
Infant Bacterial Therapeutics AB stock drug pipeline
kr 66.00
At close:-7.30 (-9.96%)
Want to see SE:IBT.B full AI Analyst Report?
Infant Bacterial Therapeutics AB (IBT.B) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibp-9414 | Necrotizing Enterocolitis | Phase III | Active Not Recruiting | IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study | Jun 05, 2019 | ― |
| Ibp-9414 | Necrotizing Enterocolitis | Phase II | Completed | IBP-9414 for the Prevention of Necrotizing Enterocolitis | Jun 02, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibp-9414 | Phase III | Necrotizing Enterocolitis | Active Not Recruiting | IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study | Jun 05, 2019 | ― |
| Ibp-9414 | Phase II | Necrotizing Enterocolitis | Completed | IBP-9414 for the Prevention of Necrotizing Enterocolitis | Jun 02, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Infant Bacterial Therapeutics (SE:IBT.B) have in its pipeline
Infant Bacterial Therapeutics AB SE:IBT.B is currently developing the following drugs: Ibp-9414. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

